Future heart failure research and drug trials should include far more women than in the past. The current state of knowledge places women at a distinct disadvantage as they are often treated identically to men, who have received the bulk of research attention.
There have been many studies showing the benefits of multidisciplinary discharge and management teams, but relatively little has been done to discover exactly what aspects of these teams really work. For example, which members of the teams are contributing the most? Are certain members even necessary? Perhaps certain key members are necessary, and make a large positive impact. Perhaps other members only make things worse.
Information pertaining to the risk factors and physiological differences between men and women suffering from HF from different ethnic backgrounds is lacking. Death rates for African American’s are higher than for Caucasian’s. The reasons for this are still unknown.